National Lab Briefs

Fermilab Faces Life Without The SSC The selection of Texas as the site of the multibillion-dollar superconducting supercollider last month (see story, page 1) has big loser Fermilab worrying about its future. Within hours of the selection, recent Nobel laureate Leon Lederman, director of the Illinois accelerator complex, launched a preemptive strike against an expected decline in morale by assuring the lab’s nearly 400 physicists and engineers that a proposed expansion of the lab’s

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The selection of Texas as the site of the multibillion-dollar superconducting supercollider last month (see story, page 1) has big loser Fermilab worrying about its future. Within hours of the selection, recent Nobel laureate Leon Lederman, director of the Illinois accelerator complex, launched a preemptive strike against an expected decline in morale by assuring the lab’s nearly 400 physicists and engineers that a proposed expansion of the lab’s own Tevatron accelerator would keep the facility productive well into the next century.

But members of the Department of Energy’s High Energy Physics Advisory Panel, who gathered for a routine meeting in Washington a few days later, were far less confident than Lederman about Fermilab’s ability to retain its enviable place atop the U.S. high-energy physics heap. They pointed out that the Illinois facility’s proposed $250 million upgrade would occur in the mid-1990s—a period that coincides with the peak of planned construction ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies